Board of Directors

Frédéric Porte (Chairman)

President, Médipress Management Inc. and Venture Partner, Genesys Capital Partner.

Mr. Frederic Porte is a seasoned entrepreneur and businessman with more than 25 years of experience in the life sciences industry. During his career, Mr. Porte has founded 3 successful companies. He is currently the President and Founder of Medipress Management Inc., a firm offering financial and strategic services to healthcare and venture capital organizations for the evaluation of M&A and strategic alliances. Prior to that, he founded in 1987 Clinidata, a software and communication company developed in association with Royal Bank Capital Corporation and specialized in healthcare applications. Clinidata developed effective and sophisticated technologies supported by multinational corporations such as Merck, Pfizer, J&J, Schering Plough and Smith Kline Beecham, combined with strategic alliances with managed care organizations and professional associations. The company was acquired in 1994 by the pharmaceutical company Hoechst Marion Roussel. In 1980, he created and managed L’Actualité Médicale, a leading Canadian medical publishing company which was later acquired by MacLean Hunter.  Mr. Porte has a degree in Business Administration and Finance from l’École Supérieure de Commerce de Lyon (France) and a D.E.A. in Information Sciences from the University of Sorbonne (France). Mr. Porte is a member of the Board of Directors of Labopharm Inc. He is also a director of Angelus Investment Corporation and Venture Partner of Genesys Capital Partner.

Bonabes de Rougé, M.D.

Former Senior Executive Vice-President and CSO, Ambrilia

Formerly President and Chief Executive Officer of Cellpep S.A., Dr. de Rougé has more than 30 years of experience in the international pharmaceutical industry where he occupied various scientific executive positions with Servier and Beaufour-Ipsen. During the last 20 years, he developed a solid expertise in peptide development and is a seasoned manager of the entire drug development process at the international level. Dr. de Rougé is a Doctor of Medicine and holds a Chemistry-Biology Diploma from Paris University.

Paul-Henry Schmelck, M.D.

Former Director of Investments, OTC Asset Management (France)

Dr. Paul-Henry Schmelck has more than 10 years of experience in biotech and pharmaceutical financing, and 20 years in medical practice and research as well as in pharmaceutical and biotech development. Before joining OTC Asset Management, a Paris-based venture capital fund with more than €250 million under management, he was the founder, President & CEO, of PrimeBioTech a gene therapy company developing therapeutic products to treat genetic diseases of the retina. He also managed banking operations related to the biotech, pharmaceutical, medical and cosmetic industries for the Union d’études et Investissements (“UI”), Crédit Agricole’s investment branch. In that capacity, Dr. Schmelck advised and assisted numerous European and U.S. companies in Mergers & Acquisitions, licensing and research agreements, joint-ventures and technology transfers. In addition, Dr. Schmelck headed a scientific group of 150 professionals at Elf Sanofi as Biotechnology Research Director. He practiced in general pediatrics, nephrology and endocrinology at the Hôpital Necker Enfants Malades. He published over thirty articles in scientific and medical journals and has participated to lectures on a numerous number of subjects in France and abroad. He received his M.D. with specialization in pediatrics and a Masters degree of advanced studies in molecular and cellular pharmacology from the University of Paris. He followed INSEAD’s Advanced Management Program (1987).

Philip S. Tabbiner, Ph.D.

Senior Vice-President, K-12 Learning and Development, Educational Testing System (USA)

Dr. Philip S. Tabbiner is a veteran of the pharmaceutical and diagnostics industry. He has served in executive positions with Chiron, Bayer Healthcare, Dupont-Merck, aaiPharma, BioCentrex and TRx Pharmaceuticals. Over his 25-year career he has worked in nearly every commercial facet of the pharmaceutical and diagnostics businesses.

 

Financial Reports